CompoAtlas

Huile essentielle de Romarin à verbénone

Food supplement declared in France, declaration No 2019-11-651, decision dated 18 November 2019

Huile essentielle de Romarin à verbénone is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). None of the rules we check flags an issue with its declared composition.

Brand
not provided
Food business operator placing the product on the market
SAS LABORATOIRE DE COMBE D'ASE (LABORATOIRE DAZONT)
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Compte-gouttes
Daily dose
3 gouttes
Directions for use
1 goutte, 3 fois par jour sur un support neutre (miel, sucre, huile végétale).
Not recommended for (according to the manufacturer)
Femmes allaitantes, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Nourrissons (moins de 1 an), Utilisation prolongée
Objectives stated by the manufacturer (these are not authorised claims)
Digestion

Declaration 166357, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

None of the rules we check applies to the declared ingredients.

Declared composition

Plants

PlantPartPreparationPer day
Rosmarinus officinalis L.Essence (sommités fleuries)Distillation81 mg

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Tenir hors de portée des enfants. A conserver dans un endroit frais, sec et à l'abri de de la lumière et de la chaleur. Les compléments alimentaires doivent être utilisés dans le cadre d'un mode de vie sain et ne pas être utilisés comme substituts d'un régime alimentaire varié et équilibré. Ce produit n'est pas un médicament. Demandez conseil à un professionnel de santé. Déconseillé chez les femmes enceintes ou allaitantes et chez les enfants de moins de 12 ans. Déconseillé en cas de calculs biliaires Ne pas dépasser la dose journalière recommandée. Eviter un usage prolongé.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Rosmarinus officinalis L.
    Read the warning, when it applies and the studies cited

    ROSEMARY – ROSMARINUS OFFICINALIS Oral

    Route of administration: Oral (ESCOP 2003)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

    ROSEMARY - ROSMARINUS OFFICINALIS Topical

    Route of administration: Topical (ESCOP 2003)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have large open wounds, skin lesions, feverish conditions, acute inflammation, severe circulatory disorders or hypertension (ESCOP 2003).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Barnes et al. 2007; ESCOP 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 29 May 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2019. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line